Immune Checkpoint Inhibitors-Induced Hepatitis

Area of Science:

• Oncology
• Immunology
• Hepatology

Background:

• Immune checkpoint inhibitors (ICIs), including CTLA-4 and PD-1/PD-L1 inhibitors, are widely used in cancer treatment.
• Hepatotoxicity is a recognized side effect of ICI therapy.
• Early identification and management of ICI-induced liver injury are crucial.

Purpose of the Study:

• To summarize the clinical presentation, diagnosis, and management of immune checkpoint inhibitor-induced hepatitis.
• To highlight the importance of recognizing this adverse event in cancer patients receiving ICIs.

Main Methods:

• Literature review of studies on ICI-induced hepatotoxicity.
• Analysis of clinical data regarding timing, symptoms, and laboratory findings.
• Discussion of diagnostic criteria and treatment strategies.

Main Results:

• Hepatotoxicity from ICIs commonly presents with elevated liver enzymes (AST and ALT) 8-12 weeks post-initiation.
• The condition is often asymptomatic but can manifest with constitutional symptoms or severe liver injury.
• Diagnosis involves excluding other causes of hepatitis.

Conclusions:

• ICI-induced hepatitis is a significant adverse event requiring vigilant monitoring.
• Management may involve ICI discontinuation and immunosuppressive therapy.
• Further research is needed to optimize the prevention and treatment of ICI-related liver injury.